Skip to main content
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer
May 9, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM
May 3, 2022
MedinCell provides additional information regarding the new drug application for mdc-IRM
April 19, 2022
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
April 19, 2022
MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE
March 28, 2022
Publication of the 2022 financial calendar
January 13, 2022
MedinCell publishes its financial results and activity report for the first half of 2021-2022
December 8, 2021
Videoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021
December 2, 2021
MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)
December 1, 2021
